Calcipotriene/betamethasone dipropionate: a new topical ointment for psoriasis

Author: Guenther, Lyn C

Source: Expert Review of Dermatology, Volume 1, Number 6, December 2006 , pp. 791-797(7)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Topical steroids and calcipotriene are the mainstay of treatment for mild-to-moderate psoriasis. They are used as monotherapy or in combination in an a.m./p.m. regimen owing to drug incompatibility. Recently, the US FDA approved a once-daily stable two-compound ointment containing calcipotriene and betamethasone dipropionate (Taclonex^®). This product has been marketed in other countries under the names Dovobet^® and Daivobet^®. It is convenient with a faster speed of onset and greater efficacy than its individual ingredients or tacalcitol. After 4 weeks of therapy, the psoriasis area and severity index is reduced by approximately 70% and half of the patients have absent or very mild disease. Furthermore, more than half of the patients reach PASI-75 after 4 weeks of treatment. The calcipotriene/betamethasone dipropionate ointment is well tolerated with a safety profile similar to betamethasone dipropionate. It is associated with 50 and 75% fewer cutaneous adverse events than calcipotriene and tacalcitol, respectively.

Keywords: betamethasone dipropionate; calcipotriene; calcipotriol; fixed combination; psoriasis

Document Type: Research article

DOI: http://dx.doi.org/10.1586/17469872.1.6.791

Publication date: 2006-12-01

More about this publication?

Expert Review of Dermatology provides rapid publication of commentary and analysis on the latest research and clinical advances in all areas of dermatology, and of the challenges for this diverse specialty in a new medical era.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites